In extended analyses, melanoma patients who responded well to rVV-B7.1 had a lower frequency of ILT2-expressing FoxP3+ CD4+ and CD8+ T cells both in the blood and the tumour [71]. This evidence concerns the gene CD8A and neoplasm.